Eqis Capital Management, Inc. Amgen Inc Transaction History

Eqis Capital Management, Inc.

$1.21 Billion
Q3 2024

A detailed history of Eqis Capital Management, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Eqis Capital Management, Inc. holds 6,425 shares of AMGN stock, worth $1.68 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares

6,425

Previous 6,608 2.77%

Holding current value

$1.68 Million

Previous $2.06 Million 0.29%

% of portfolio

0.17%

Previous 0.18%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$309.38 - $337.38 $56,616 - $61,740	-183 Reduced 2.77%	6,425 $2.07 Million
Q2 2024 Aug 13, 2024	SELL	$262.75 - $319.31 $251,977 - $306,218	-959 Reduced 12.67%	6,608 $2.06 Million
Q1 2024 May 14, 2024	BUY	$268.87 - $324.56 $59,958 - $72,376	223 Added 3.04%	7,567 $2.15 Million
Q4 2023 Feb 14, 2024	SELL	$255.7 - $288.46 $195,610 - $220,671	-765 Reduced 9.43%	7,344 $2.12 Million
Q3 2023 Nov 13, 2023	BUY	$218.65 - $271.46 $135,344 - $168,033	619 Added 8.26%	8,109 $2.18 Million
Q2 2023 Aug 14, 2023	SELL	$214.27 - $253.37 $11,784 - $13,935	-55 Reduced 0.73%	7,490 $1.66 Million
Q1 2023 May 15, 2023	SELL	$225.79 - $275.2 $1.41 Million - $1.72 Million	-6,252 Reduced 45.31%	7,545 $1.82 Million
Q4 2022 Feb 14, 2023	SELL	$229.03 - $291.01 $115,660 - $146,960	-505 Reduced 3.53%	13,797 $3.62 Million
Q3 2022 Oct 24, 2022	BUY	$224.46 - $253.15 $101,455 - $114,423	452 Added 3.26%	14,302 $3.22 Million
Q2 2022 Aug 08, 2022	BUY	$230.71 - $256.74 $149,038 - $165,854	646 Added 4.89%	13,850 $3.37 Million
Q1 2022 May 16, 2022	BUY	$219.27 - $242.57 $761,743 - $842,688	3,474 Added 35.7%	13,204 $3.19 Million
Q4 2021 Feb 14, 2022	SELL	$198.88 - $227.6 $716,564 - $820,042	-3,603 Reduced 27.02%	9,730 $2.19 Million
Q3 2021 Nov 12, 2021	SELL	$212.27 - $248.7 $37,784 - $44,268	-178 Reduced 1.32%	13,333 $2.84 Million
Q2 2021 Aug 12, 2021	SELL	$233.58 - $259.14 $15,649 - $17,362	-67 Reduced 0.49%	13,511 $3.29 Million
Q1 2021 May 14, 2021	SELL	$221.91 - $258.6 $186,626 - $217,482	-841 Reduced 5.83%	13,578 $3.38 Million
Q4 2020 Feb 11, 2021	SELL	$216.38 - $257.67 $174,835 - $208,197	-808 Reduced 5.31%	14,419 $3.32 Million
Q3 2020 Nov 10, 2020	SELL	$234.65 - $260.95 $351,036 - $390,381	-1,496 Reduced 8.95%	15,227 $3.87 Million
Q2 2020 Aug 10, 2020	SELL	$197.81 - $242.74 $730,907 - $896,924	-3,695 Reduced 18.1%	16,723 $3.94 Million
Q1 2020 May 12, 2020	BUY	$182.24 - $241.7 $414,596 - $549,867	2,275 Added 12.54%	20,418 $4.68 Million
Q4 2019 Jan 24, 2020	SELL	$189.21 - $243.2 $272,462 - $350,208	-1,440 Reduced 7.35%	18,143 $4.37 Million
Q3 2019 Nov 05, 2019	SELL	$174.11 - $208.62 $420,301 - $503,608	-2,414 Reduced 10.97%	19,583 $3.79 Million
Q2 2019 Jul 18, 2019	SELL	$166.7 - $195.41 $198,373 - $232,537	-1,190 Reduced 5.13%	21,997 $4.05 Million
Q1 2019 Apr 18, 2019	SELL	$180.87 - $203.88 $2.59 Million - $2.92 Million	-14,317 Reduced 38.17%	23,187 $4.41 Million
Q4 2018 Jan 25, 2019	SELL	$178.4 - $208.25 $780,856 - $911,510	-4,377 Reduced 10.45%	37,504 $7.3 Million
Q3 2018 Oct 17, 2018	SELL	$185.29 - $208.89 $164,537 - $185,494	-888 Reduced 2.08%	41,881 $8.24 Million
Q2 2018 Jul 27, 2018	BUY	$166.05 - $186.51 $225,994 - $253,840	1,361 Added 3.29%	42,769 $7.9 Million
Q1 2018 Apr 06, 2018	SELL	$169.43 - $198.0 $819,024 - $957,132	-4,834 Reduced 10.45%	41,408 $7.06 Million
Q4 2017 Jan 25, 2018	BUY	$168.79 - $188.59 $2.35 Million - $2.62 Million	13,907 Added 43.01%	46,242 $8.04 Million
Q3 2017 Oct 03, 2017	BUY	$167.29 - $191.0 $5.41 Million - $6.18 Million	32,335	32,335 $6.03 Million

Others Institutions Holding AMGN

# of Institutions

3,119

Shares Held

407M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $140B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eqis Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Eqis Capital Management, Inc. with notifications on news.

Account

Eqis Capital Management, Inc. Amgen Inc Transaction History